MA48464A - Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques - Google Patents
Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiquesInfo
- Publication number
- MA48464A MA48464A MA048464A MA48464A MA48464A MA 48464 A MA48464 A MA 48464A MA 048464 A MA048464 A MA 048464A MA 48464 A MA48464 A MA 48464A MA 48464 A MA48464 A MA 48464A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylated
- viscosity
- reducing
- therapeutic polypeptides
- viscous compositions
- Prior art date
Links
- 239000004475 Arginine Substances 0.000 title 1
- 108010016626 Dipeptides Proteins 0.000 title 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762492020P | 2017-04-28 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA48464A true MA48464A (fr) | 2020-03-04 |
Family
ID=62165708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA048464A MA48464A (fr) | 2017-04-28 | 2018-04-27 | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques |
Country Status (6)
Country | Link |
---|---|
US (1) | US20200048367A1 (fr) |
EP (1) | EP3615069A1 (fr) |
AU (1) | AU2018258676A1 (fr) |
CA (1) | CA3059369A1 (fr) |
MA (1) | MA48464A (fr) |
WO (1) | WO2018201064A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020205716A1 (fr) * | 2019-04-01 | 2020-10-08 | Genentech, Inc. | Compositions et procédés de stabilisation de formulations contenant des protéines |
AU2020263318A1 (en) * | 2019-04-23 | 2021-10-21 | Amgen Inc. | The use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations |
EP4262868A1 (fr) * | 2020-12-17 | 2023-10-25 | Astrazeneca AB | Formulations d'anticorps anti-il5r |
KR20240046881A (ko) * | 2021-08-12 | 2024-04-11 | 암젠 인크 | 항체 제형 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US6767892B1 (en) * | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
EA014802B1 (ru) | 2001-08-23 | 2011-02-28 | Генмаб А/С | АНТИТЕЛА К ИНТЕРЛЕЙКИНУ 15 (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ИММУНОКОНЪЮГАТ НА ИХ ОСНОВЕ, ГИБРИДОМА, ТРАНСФЕКТОМА, ТРАНСГЕННОЕ ЖИВОТНОЕ, ЭКСПРЕССИОННЫЙ ВЕКТОР (ВАРИАНТЫ) И НУКЛЕИНОВАЯ КИСЛОТА ДЛЯ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ (ВАРИАНТЫ) И СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ИЛ-15, СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОДУКЦИИ TNF-α И СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОЛИФЕРАЦИИ КЛЕТОК |
WO2006081171A1 (fr) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Anticorps anti-amyloide humanise |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
AU2008265128A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
RU2012151500A (ru) * | 2010-05-03 | 2014-06-10 | Дженентек, Инк. | Композиции и способы, пригодные для снижения вязкости белковосодержащих составов |
WO2015196091A1 (fr) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Composés excipient réduisant la viscosité pour formulations à base de protéines |
MX2017000527A (es) * | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
SG11201703152RA (en) | 2014-10-23 | 2017-05-30 | Amgen Inc | Reducing viscosity of pharmaceutical formulations |
-
2018
- 2018-04-27 CA CA3059369A patent/CA3059369A1/fr active Pending
- 2018-04-27 WO PCT/US2018/029981 patent/WO2018201064A1/fr unknown
- 2018-04-27 AU AU2018258676A patent/AU2018258676A1/en active Pending
- 2018-04-27 EP EP18724732.5A patent/EP3615069A1/fr active Pending
- 2018-04-27 US US16/607,673 patent/US20200048367A1/en active Pending
- 2018-04-27 MA MA048464A patent/MA48464A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20200048367A1 (en) | 2020-02-13 |
WO2018201064A1 (fr) | 2018-11-01 |
EP3615069A1 (fr) | 2020-03-04 |
CA3059369A1 (fr) | 2018-11-01 |
AU2018258676A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
MA48464A (fr) | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques | |
MA51103A (fr) | Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique | |
MA43025A (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 | |
MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
MA41901A (fr) | Compositions contenant de l'ibrutinib | |
FR3031744B1 (fr) | Compositions d'additifs thermoassociatifs dont l'association est controlee et compositions lubrifiantes les contenant | |
SG11202009574RA (en) | Combinations of osteopontin and 2'-fucosyllactose for use as medicaments | |
MA49116A (fr) | Compositions pharmaceutiques contenant de l'insuline | |
MA55082A (fr) | Compositions, procédés, et kits pour l'administration de polyribonucléotides | |
MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
MD3359146T2 (ro) | Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală | |
MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
IL280183A (en) | Pocan preparations with a high degree of cleanliness and/or modified to treat fibrous adhesions | |
MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
IL280596A (en) | Anti-IL-1 antibody in a cell, its pharmaceutical preparation and its use | |
GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
MA49524A (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
MA42497A (fr) | Procédés et compositions pour la régulation sélective de l'expression protéique | |
SG11202112487QA (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
IT201700025666A1 (it) | Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari. | |
MA52796A (fr) | Compositions et procédés de détection d'une lésion cérébrale traumatique | |
IT201700085412A1 (it) | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare | |
IL276783A (en) | The composition and pharmaceutical compound containing it |